SAN FRANCISCO--(BUSINESS WIRE)--Station X, Inc., a leading developer of cloud-based genome management systems for research and precision medicine applications, today announced that Circulogene Theranostics will use its GenePool® platform to analyze and interpret data generated from their cell-free DNA (cfDNA) sequencing-based liquid biopsy services. Circulogene’s proprietary technology is capable of detecting nearly 3,000 cancer mutations on 50 well-established cancer-associated genes and can provide information on current FDA-approved and NCCN/ASCO-endorsed treatment options for the tumor DNA mutations identified.
